72209-19-9

Usage

Uses

Used in Chemical and Biological Research:
2-CHLORO-9-(2-3-O-ISOPROPYLIDENE-BETA-D-RIBOFURANOSYLURONIC ACID)ADENINE is used as a research compound for studying the structure and function of nucleic acids, particularly DNA and RNA. Its unique chemical structure allows for the investigation of its interactions with other molecules and its potential biological activity.

Upstream product

• 72635-67-7 (2S,3S,4R,5S)-2-(6-amino-2-chloro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol 
• 24639-06-3 ((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 146-77-0 2-Chloroadenosine 

Downstream Products

• 127258-46-2 2-<<4-(2-carbomethoxyetyl)phenethyl>amino>adenosine-5'-N-ethylcarboxamide hydrochloride 
• 127258-42-8 (4-{2-[6-Amino-9-((2R,3R,4S,5S)-5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-ylamino]-ethyl}-phenoxy)-acetic acid; hydrochloride 
• 124431-80-7 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride 
• 127258-44-0 (4-{2-[6-Amino-9-((2R,3R,4S,5S)-5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-ylamino]-ethyl}-phenyl)-acetic acid; hydrochloride 
• 127258-37-1 (2S,3S,4R,5R)-5-{6-Amino-2-[2-(4-chloro-phenyl)-ethylamino]-purin-9-yl}-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid ethylamide; hydrochloride 
• 127258-32-6 (2S,3S,4R,5R)-5-(6-Amino-2-phenethylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid cyclopropylamide; hydrochloride 
• 127258-40-6 (2S,3S,4R,5R)-5-[6-Amino-2-(methyl-phenethyl-amino)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid ethylamide; hydrochloride 
• 127258-35-9 (2S,3S,4R,5R)-5-(6-Amino-2-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid ethylamide; hydrochloride 
• 127258-43-9 (4-{2-[6-Amino-9-((3aR,4R,6S,6aS)-6-ethylcarbamoyl-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-9H-purin-2-ylamino]-ethyl}-phenoxy)-acetic acid tert-butyl ester 
• 120225-76-5 2-<<4-<2-(tert-butoxycarbonyl)etyl>phenethyl>amino>-2',3'-O-isopropylideneadenosine-5'-N-ethylcarboxamide 
• 127258-45-1 (4-{2-[6-Amino-9-((3aR,4R,6S,6aS)-6-ethylcarbamoyl-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-9H-purin-2-ylamino]-ethyl}-phenyl)-acetic acid tert-butyl ester 
• 127258-38-2 (3aS,4S,6R,6aR)-6-{6-Amino-2-[2-(4-chloro-phenyl)-ethylamino]-purin-9-yl}-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid ethylamide 
• 127258-39-3 (3aS,4S,6R,6aR)-6-{6-Amino-2-[2-(4-fluoro-phenyl)-ethylamino]-purin-9-yl}-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid ethylamide 
• 127258-34-8 (3aS,4S,6R,6aR)-6-(6-Amino-2-phenethylamino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid cyclopropylamide 

Relevant academic research and scientific papers

Structure-activity relationships of the sustained effects of adenosine A2A receptor agonists driven by slow dissociation kinetics

The duration of action of adenosine A2A receptor (A2A) agonists is critical for their clinical efficacy, and we sought to better understand how this can be optimized. The in vitro temporal response profiles of a panel of A2A agonists were studi

An Fc domain protein-small molecule conjugate as an enhanced immunomodulator

Proteins as well as small molecules have demonstrated success as therapeutic agents, but their pharmacologic properties sometimes fall short against particular drug targets. Although the adenosine 2a receptor (A 2AR) has been identified as a pr

THERAPEUTIC COMPOUNDS

Use of compounds of general formula (A) as medicaments is described, in particular for the treatment of pain or inflammation; wherein: (I) when X = OH, R2 = NH2, R5 = CH2OH, R6 = H , R1 is C5-C6 alkoxy, OCH2Cyclopropyl, O-(2,2,3,3-tetrafluoro-cycloButyl), phenoxy, substituted phenoxy, OCH2CH2OH, or OCH2CHF2, (5-indanyl)oxy, C1, C2, C5, or C6 alkylamino, (R) or (S)-sec-Butylamino, C5 or C6 cycloalkylamino, exo-norbornane amino, (N-methyl, N--isoamylamino), phenylamino, phenylamino with either rnethoxy or fluoro substituents, a C2 sulfone group, a C2 alkyl group, a cyano group, a CONH2 group, or 3,5-dimethylphenyl; or when X = H, R2 = NH2, R5 = CH2OH , R6 = H, R1 is n-hexyloxy; or (II) when X = OH , R1 = H, R5 = CH2OH, R6 = H, R2 is NMe2, N-(2-isopentenyl), piperazinyl, (N-Me, N-benzyl), (N-Me, N-CH2Ph(3-Br)), (N-Me, N--CH2Ph(3-CF3)), or (N-Me, N-(2-rnethoxyethyl)), or OCH2Cyclopentyl; or (III) when X = OH, R5 = CONHR3, R6 = H: R1 is H, R3 is an isopropyl group, and R2 is either NH2 or a methylamino group (NHMe) or an isoamyl group (CH2CH2CHMe2); or R1 is H, R3 is H, and R2 is NH2; or R1 is OMe, R3 is Ph, and R2 is NH2; or R1 is NHCH2CH2CH2CH2CH2Me, R3 is CH2CH2CH2Me, and R2 is NH2; or (IV) when X = OH, R1 = H, R2 = NH2, R5 = CH2NHCOR.4, R6 = H, R4 is n-propyl or NHCH2CH3; or (V) when X = OH, R5 = CH2OH, R6 = H: R1 is NHCyclohexyl when R2 is NMe2; or R1 is OMe when R2 is NHBenzyl; or (VI) when X = OH , R2 = NH2, R5 = CH2OH, R6 = Me, R1 is NHCyclohexyl or NHCyclopentyl.

2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives

There are disclosed according to the invention, compounds of formula (I) wherein R1, R2and R3are defined in the specification. Additionally, processes of preparing the compounds of formula (I), formulations containing same, and the administration of said compounds or formulations thereof in the treatment of inflammatory diseases are also disclosed.

2-(Arylalkylamino)adenosin-5'-uronamides: A New Class of Highly Selective Adenosine A2 Receptor Ligands

The synthesis and receptor-binding profiles at adenosine receptor subtypes for a series of 2-(arylalkylamino)adenosin-5'-uronamides is described.Halogenated 2-phenethylamino analogues such as 3e show greater than 200-fold selectivity for the A2 receptor s